Fig. 1
a Progression-free survival (N = 72) and b overall survival (N = 74) of patients in the anti-PD-1/TA + SBRT group and the anti-PD-1/TA alone group
Fig. 1 | Radiation Oncology
a Progression-free survival (N = 72) and b overall survival (N = 74) of patients in the anti-PD-1/TA + SBRT group and the anti-PD-1/TA alone group